头孢吡肟/恩美唑巴坦对比哌拉西林/他唑巴坦对复杂性尿路感染或急性肾盂肾炎患者临床治愈和微生物清除的影响:一项随机临床试验
这项3期随机双盲多中心非劣效试验在90个中心纳入1041例复杂性尿路感染或急性肾盂肾炎成年患者,比较头孢吡肟/恩美唑巴坦与哌拉西林/他唑巴坦的疗效。主要分析集中,头孢吡肟/恩美唑巴坦组总体治疗成功率79.1%(273/345),哌拉西林/他唑巴坦组58.9%(196/333),组间差异21.2%(95%CI 14.3%至27.9%),达到非劣效和优效标准。
要点
- 头孢吡肟/恩美唑巴坦组总体治疗成功率79.1%(273/345),哌拉西林/他唑巴坦组58.9%(196/333)。
- 组间差异21.2%(95%CI 14.3%至27.9%),达到预设非劣效界值-10%及优效标准。
- 治疗中出现的不良事件发生率头孢吡肟/恩美唑巴坦组50.0%(258/516),哌拉西林/他唑巴坦组44.0%(228/518),多为轻至中度。
核心结论
- 在革兰阴性病原体所致的复杂性尿路感染或急性肾盂肾炎患者中,头孢吡肟/恩美唑巴坦对比哌拉西林/他唑巴坦在临床治愈联合微生物清除的主要结局上达到非劣效和优效标准。
- 作者指出需进一步研究以确定头孢吡肟/恩美唑巴坦在复杂性尿路感染和肾盂肾炎治疗中的潜在作用。
研究设计与样本
- 3期、随机、双盲、阳性对照、多中心、非劣效临床试验,在欧洲、北美和中美洲、南美及南非的90个中心开展。
- 招募时间为2018年9月24日至2019年11月2日,末次随访于2019年11月26日完成。
- 纳入18岁及以上、临床诊断为革兰阴性尿路病原体所致复杂性尿路感染或急性肾盂肾炎的成年患者。
- 随机分配至头孢吡肟2 g/恩美唑巴坦0.5 g组(n=520)或哌拉西林4 g/他唑巴坦0.5 g组(n=521),每8小时2小时输注,疗程7天(基线血培养阳性者最长14天)。
- 共随机1041例患者(平均年龄54.7岁;女性573例[55.0%]),1034例(99.3%)接受研究药物,995例(95.6%)完成试验。
主要发现
- 主要分析集定义为接受任意量研究药物、基线革兰阴性病原体对两种治疗均不耐药且尿培养≥10^5 CFU/mL或同时血尿培养存在同一病原体的患者。
- 主要结局为总体治疗成功(临床治愈联合微生物清除[尿菌<10^3 CFU/mL])。
- 主要分析集中,头孢吡肟/恩美唑巴坦组总体治疗成功率为79.1%(273/345),哌拉西林/他唑巴坦组为58.9%(196/333)。
- 组间差异为21.2%(95%CI 14.3%至27.9%),预设非劣效界值为-10%,采用分层Newcombe法计算双侧95%CI。
- 治疗中出现的不良事件发生率头孢吡肟/恩美唑巴坦组为50.0%(258/516),哌拉西林/他唑巴坦组为44.0%(228/518);大多数为轻至中度(分别为89.9% vs 88.6%)。
关键数值与推荐
- 非劣效界值预设为-10%。
- 主要分析集要求基线尿培养≥10^5 CFU/mL或血尿培养同一病原体。
- 微生物清除定义为尿菌<10^3 CFU/mL。
- 头孢吡肟/恩美唑巴坦剂量为2 g/0.5 g,哌拉西林/他唑巴坦剂量为4 g/0.5 g,每8小时2小时输注,疗程7天(基线血培养阳性者最长14天)。
临床怎么用
- 原文未据此给出推荐。
- 作者结论指出需进一步研究以确定头孢吡肟/恩美唑巴坦在复杂性尿路感染和肾盂肾炎治疗中的潜在作用。
局限性
- 作者指出需进一步研究以确定头孢吡肟/恩美唑巴坦在复杂性尿路感染和肾盂肾炎治疗中的潜在作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cefepime/enmetazobactam is a novel β-lactam/β-lactamase inhibitor combination and a potential empirical therapy for resistant gram-negative infections. OBJECTIVE: To evaluate whether cefepime/enmetazobactam was noninferior to piperacillin/tazobactam for the primary outcome of treatment efficacy in patients with complicated urinary tract infections (UTIs) or acute pyelonephritis. DESIGN, SETTING, AND PARTICIPANTS: A phase 3, randomized, double-blind, active-controlled, multicenter, noninferiority clinical trial conducted at 90 sites in Europe, North and Central America, South America, and South Africa. Recruitment occurred between September 24, 2018, and November 2, 2019. Final follow-up occurred November 26, 2019. Participants were adult patients aged 18 years or older with a clinical diagnosis of complicated UTI or acute pyelonephritis caused by gram-negative urinary pathogens. INTERVENTIONS: Eligible patients were randomized to receive either cefepime, 2 g/enmetazobactam, 0.5 g (n = 520), or piperacillin, 4 g/tazobactam, 0.5 g (n = 521), by 2-hour infusion every 8 hours for 7 days (up to 14 days in patients with a positive blood culture at baseline). MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients in the primary analysis set (patients who received any amount of study drug with a baseline gram-negative pathogen not resistant to either treatment and ≥105 colony-forming units [CFU]/mL in urine culture or the same pathogen present in concurrent blood and urine cultures) who achieved overall treatment success (defined as clinical cure combined with microbiological eradication [<103 CFU/mL in urine] of infection). Two-sided 95% CIs were computed using the stratified Newcombe method. The prespecified noninferiority margin was -10%. If noninferiority was established, a superiority comparison was also prespecified. RESULTS: Among 1041 patients randomized (mean age, 54.7 years; 573 women [55.0%]), 1034 (99.3%) received study drug and 995 (95.6%) completed the trial. Among the primary analysis set, the primary outcome occurred in 79.1% (273/345) of patients receiving cefepime/enmetazobactam compared with 58.9% (196/333) receiving piperacillin/tazobactam (between-group difference, 21.2% [95% CI, 14.3% to 27.9%]). Treatment-emergent adverse events occurred in 50.0% (258/516) of patients treated with cefepime/enmetazobactam and 44.0% (228/518) with piperacillin/tazobactam; most were mild to moderate in severity (89.9% vs 88.6%, respectively). A total of 1.7% (9/516) of participants who received cefepime/enmetazobactam and 0.8% (4/518) of those who received piperacillin/tazobactam did not complete the assigned therapy due to adverse events. CONCLUSIONS AND RELEVANCE: Among patients with complicated UTI or acute pyelonephritis caused by gram-negative pathogens, cefepime/enmetazobactam, compared with piperacillin/tazobactam, met criteria for noninferiority as well as superiority with respect to the primary outcome of clinical cure and microbiological eradication. Further research is needed to determine the potential role for cefepime/enmetazobactam in the treatment of complicated UTI and pyelonephritis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03687255.
引用
- Kaye KS, Belley A, Barth P, et al. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. JAMA. 2022. PMID: 36194218. doi:10.1001/jama.2022.17034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。